Application of hyaluronic acid in heart failure diagnosis after myocardial infarction and cardiac function prognosis evaluation

Abstract

The invention discloses application of hyaluronic acid in post-myocardial infarction heart failure diagnosis and cardiac function prognosis evaluation, belongs to the field of biomarkers, and aims to solve the problems of post-myocardial infarction heart failure diagnosis and cardiac function prognosis evaluation. The technical key point is application of hyaluronic acid HA as a marker in preparation of a product for diagnosis of heart failure after myocardial infarction and prognosis evaluation of cardiac function of a myocardial infarction patient, and the effect is that hyaluronic acid HA can be applied to diagnosis of heart failure after myocardial infarction and prognosis evaluation of cardiac function as a biomarker.

Description

Technical Field

[0001] The present invention belongs to the field of biomarkers, and specifically relates to the application of hyaluronan (HA), a glycocalyx shedding marker, in the diagnosis of heart failure after myocardial infarction and the evaluation of cardiac function prognosis. Background Art

[0002] Myocardial infarction is a highly lethal and disabling disease, with the characteristics of rapid onset, frequent heart failure and poor prognosis. Post-myocardial infarction heart failure is one of the most common complications of myocardial infarction. Studies have shown that the incidence of post-myocardial infarction heart failure in patients with myocardial infarction is as high as 19.3% within 7 days. Among them, according to the left ventricular ejection fraction (LVEF), post-myocardial infarction heart failure can be divided into heart failure with reduced ejection fraction (HFrEF, LVEF <40%), heart failure with preserved ejection fraction (HFpEF, LVEF ≥ 50%) and heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 40% to 49%). Heart failure with reduced ejection fraction is more prone to serious complications such as cardiogenic shock, heart rupture and sudden death because of its large loss of myocardium leading to rapid decline in cardiac function. However, the existing technology for the diagnosis of post-myocardial infarction heart failure types still relies on cardiac color Doppler ultrasound examinations, and lacks biomarkers that can screen post-myocardial infarction heart failure early, especially for identifying HFrEF. In addition, worsening of cardiac function within one month after discharge (ejection fraction decreases by more than 10%) is also an important sign of poor long-term prognosis for patients. However, for patients with preserved cardiac function after myocardial infarction, how to predict whether their cardiac function will worsen within 30 days is still a major clinical problem. Finding biomarkers that can evaluate the prognosis of cardiac function has significant reference significance for the subsequent treatment of patients.

[0003] Vascular glycocalyx is the general term for the polysaccharide-protein complex covering the surface of the apical membrane of vascular endothelial cells. Hyaluronan (HA) is a glycosaminoglycan that connects to endothelial cells through core proteins and other backbone pillars. Studies have shown that vascular glycocalyx changes under thrombotic and inflammatory conditions, which can cause hyaluronan shedding and changes in the sulfation pattern of heparan sulfate. However, in the past, there have only been studies on glycocalyx levels and the diagnosis of inflammatory diseases. There are currently no reports on the relationship between glycocalyx levels and changes in cardiac structure and function after myocardial infarction.

[0004] Therefore, finding biomarkers that can assess heart failure after myocardial infarction, especially markers that can achieve both diagnosis and prognosis assessment, is of great significance in the diagnosis and treatment of myocardial infarction. Summary of the invention

[0005] On the first aspect, the HA of the present application can be used as a biomarker to solve the problem of diagnosing heart failure after myocardial infarction. According to some embodiments of the present application, hyaluronic acid (HA) is used as a marker in the preparation of a product for diagnosing heart failure after myocardial infarction in patients with myocardial infarction.

[0006] According to some embodiments of the present application, hyaluronic acid (HA) is used as a marker in the preparation of a diagnostic product for post-myocardial infarction heart failure in patients with myocardial infarction, and the sample is derived from the serum of patients with myocardial infarction.

[0007] According to some embodiments of the present application, hyaluronic acid (HA) is used as a marker in the preparation of a product for diagnosing heart failure after myocardial infarction in patients with myocardial infarction, and the product includes a reagent or a kit.

[0008] According to some embodiments of the present application, hyaluronic acid (HA) is used as a marker in the preparation of a product for diagnosing post-myocardial infarction heart failure in patients with myocardial infarction, and the diagnosis of post-myocardial infarction heart failure is achieved in the following manner: the HA level in the serum of the subject being tested is detected by the product, and when the HA level in the serum of the subject being tested contains or exceeds a threshold value, it is judged that the subject being tested suffers from post-myocardial infarction heart failure.

[0009] According to the use of hyaluronic acid (HA) as a marker in the preparation of a diagnostic product for post-myocardial infarction heart failure in patients with myocardial infarction in some embodiments of the present application, the threshold value is 90.88 ng / ml, and the threshold value is the first threshold value;

[0010] According to the use of hyaluronic acid (HA) as a marker in the preparation of a diagnostic product for post-myocardial infarction heart failure in patients with myocardial infarction in some embodiments of the present application, the threshold value is 131.37 ng / ml, and it is judged that the subject being tested suffers from post-myocardial infarction heart failure with reduced ejection fraction, and the threshold value is the second threshold value;

[0011] According to some embodiments of the present application, hyaluronic acid (HA) is used as a marker in the preparation of a diagnostic product for post-myocardial infarction heart failure in patients with myocardial infarction. When the HA level in the serum of the subject is detected between the first threshold value and the second threshold value, the subject is judged to be suffering from post-myocardial infarction heart failure with preserved ejection fraction or with mildly reduced ejection fraction.

[0012] In a second aspect, according to some embodiments of the present application, a reagent for quantitatively detecting a marker is used in the preparation of a diagnostic product for post-myocardial infarction heart failure in patients with myocardial infarction, wherein the marker includes HA;

[0013] According to the use of a reagent for quantitatively detecting a marker in some embodiments of the present application in the preparation of a diagnostic product for post-myocardial infarction heart failure in patients with myocardial infarction, the reagent is used to detect the HA level in the serum of the subject being detected. When the HA level in the serum of the subject being detected contains or exceeds a threshold value, it is determined that the subject being detected suffers from post-myocardial infarction heart failure.

[0014] According to the use of a reagent for quantitatively detecting a marker in preparing a diagnostic product for post-myocardial infarction heart failure in patients with myocardial infarction in some embodiments of the present application, the threshold value is 90.88 ng / ml, and the threshold value is the first threshold value.

[0015] According to the use of reagents for quantitatively detecting markers in the preparation of a diagnostic product for post-myocardial infarction heart failure in patients with myocardial infarction in some embodiments of the present application, the threshold value is 131.37 ng / ml, and it is judged that the subject being tested suffers from post-myocardial infarction heart failure with reduced ejection fraction, and the threshold value is the second threshold value.

[0016] According to the use of reagents for quantitatively detecting markers in some embodiments of the present application in the preparation of diagnostic products for post-myocardial infarction heart failure in patients with myocardial infarction, when the HA level in the serum of the subject is detected between the first threshold value and the second threshold value, the subject is judged to be suffering from post-myocardial infarction heart failure with preserved ejection fraction or with mildly reduced ejection fraction.

[0017] On the third aspect, according to some embodiments of the present application, a system for diagnosing heart failure after myocardial infarction in patients with myocardial infarction includes a detection device, one or more processors, a memory, and one or more programs; wherein:

[0018] The detection device obtains the level of a marker in the serum of the subject being detected, wherein the marker includes HA;

[0019] The one or more programs are stored in the memory, and the one or more programs include instructions. When the instructions are executed by the electronic device, the electronic device performs the following method:

[0020] The level of the marker in the serum of the subject obtained by the detection device is compared with the threshold value stored in the processor. When the HA level in the serum of the subject exceeds the threshold value, it is determined that the subject suffers from post-myocardial infarction heart failure.

[0021] According to the post-myocardial infarction heart failure diagnosis system for myocardial infarction patients in some embodiments of the present application, the threshold value is 90.88 ng / ml, and the threshold value is the first threshold value.

[0022] According to the post-myocardial infarction heart failure diagnosis system for patients with myocardial infarction in some embodiments of the present application, the threshold value is 131.37 ng / ml, and it is judged that the subject is suffering from post-myocardial infarction heart failure with reduced ejection fraction, and the threshold value is the second threshold value.

[0023] According to the post-myocardial infarction heart failure diagnosis system for patients with myocardial infarction in some embodiments of the present application, when the HA level in the serum of the detected subject is detected between the first threshold value and the second threshold value, it is judged that the detected subject suffers from post-myocardial infarction heart failure with preserved ejection fraction or with mildly reduced ejection fraction.

[0024] In a fourth aspect, according to some embodiments of the present application, HA is used as a marker in the preparation of a product for assessing the prognosis of cardiac function in patients with myocardial infarction after myocardial infarction.

[0025] According to some embodiments of the present application, HA is used as a marker in the preparation of a product for evaluating the prognosis of cardiac function in patients with myocardial infarction after myocardial infarction, and the sample is derived from the serum of patients with myocardial infarction.

[0026] According to some embodiments of the present application, HA is used as a marker in the preparation of a product for evaluating the prognosis of cardiac function in patients with myocardial infarction after myocardial infarction, and the product includes a reagent or a kit.

[0027] According to some embodiments of the present application, HA is used as a marker in the preparation of a product for evaluating the prognosis of cardiac function after myocardial infarction in patients with myocardial infarction, and the prognosis of cardiac function after myocardial infarction is achieved in the following manner: the HA level in the serum of the subject being tested is detected by the product, and when the HA level in the serum of the subject being tested contains or exceeds a threshold value, it is judged that the subject being tested will have a deterioration in cardiac function within 1 month.

[0028] According to some embodiments of the present application, when HA is used as a marker in the preparation of a product for evaluating the prognosis of cardiac function in patients with myocardial infarction, the threshold is 92.21 ng / m, which is the third threshold.

[0029] In a fifth aspect, according to some embodiments of the present application, a reagent for quantitatively detecting a marker is used in the preparation of a method for evaluating the prognosis of cardiac function after myocardial infarction, wherein the marker includes HA.

[0030] In a sixth aspect, according to some embodiments of the present application, a system for screening, diagnosing, and detecting heart failure after myocardial infarction includes a detection device, one or more processors, a memory, and one or more programs; wherein:

[0031] The detection device obtains the level of a marker in the serum of the subject being detected, wherein the marker includes HA;

[0032] The one or more programs are stored in the memory, and the one or more programs include instructions. When the instructions are executed by the electronic device, the electronic device performs the following method:

[0033] The level of the marker in the serum of the subject obtained by the detection device is compared with the threshold value stored in the processor. When the HA level in the serum of the subject is detected to contain or exceed the threshold value, it is determined that the heart function of the subject will deteriorate within 1 month.

[0034] According to the post-myocardial infarction heart failure screening, diagnosis and detection system in some embodiments of the present application, the threshold value is 92.21 ng / m, and the threshold value is the third threshold value.

[0035] Beneficial effects: The present invention screens out serum HA, a marker that can be used for the diagnosis of post-myocardial infarction heart failure and the prognosis of cardiac function, by analyzing the relationship between serum HA levels and the development of post-myocardial infarction heart failure. Experimental verification shows that the serum HA levels of patients with post-myocardial infarction heart failure are significantly increased, and the serum HA levels of patients with reduced ejection fraction heart failure (HFrEF, LVEF <40%) are further increased. Therefore, according to the experiment, the present invention further determines the diagnostic value (first threshold) of the HA level of post-myocardial infarction heart failure and the diagnostic value (second threshold) of the HA level of post-myocardial infarction heart failure in the classification of post-myocardial infarction heart failure, and based on the first threshold and the second threshold, it can diagnose heart failure with preserved ejection fraction or heart failure with mildly reduced ejection fraction in the classification of post-myocardial infarction heart failure.

[0036] In addition, the present invention further determines the diagnostic value (third threshold) of worsening heart function within 1 month after myocardial infarction through experiments, and the possibility of worsening heart function within 1 month after myocardial infarction can be predicted based on serum HA levels.

[0037] From the above, the present invention screens new markers for clinical diagnosis of heart failure after myocardial infarction and prognosis assessment of cardiac function, and can classify and determine the type of heart failure disease, and can also predict cardiac function after heart failure. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 Serum hyaluronic acid (HA) levels in the post-myocardial infarction heart failure group and the post-myocardial infarction non-heart failure group.

[0039] Figure 2 The diagnostic value of serum hyaluronic acid (HA) levels for heart failure after myocardial infarction.

[0040] Figure 3 Serum hyaluronic acid (HA) levels in heart failure with reduced ejection fraction (HFrEF), preserved / mildly reduced ejection fraction (HFpEF / HFmrEF) and no heart failure after myocardial infarction.

[0041] Figure 4 The value of serum hyaluronic acid (HA) level in distinguishing heart failure with reduced ejection fraction (HFrEF), heart failure with preserved / mildly reduced ejection fraction (HFpEF / HFmrEF) and heart failure-free group after myocardial infarction.

[0042] Figure 5 Serum hyaluronic acid (HA) levels in the heart function deterioration group and the heart function non-deterioration group 1 month after myocardial infarction.

[0043] Figure 6 The predictive value of serum hyaluronic acid (HA) level for the deterioration of cardiac function in patients with myocardial infarction within 1 month. DETAILED DESCRIPTION

[0044] Now, various exemplary embodiments of the present invention are described in detail, which should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, characteristics and embodiments of the present invention. It should be understood that the terms described in the present invention are only for describing specific embodiments and are not used to limit the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as commonly understood by conventional technicians in the field of the present invention. Although the present invention only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein can also be used in the implementation or testing of the present invention. Without departing from the scope or spirit of the present invention, various modifications and changes can be made to the specific embodiments of the present invention description, which will be obvious to those skilled in the art. Other embodiments obtained from the description of the present invention will be obvious to the technician. The present application description and examples are exemplary only. As for the "comprising", "including", "having", "containing" and the like used herein, they are all open terms, that is, they mean including but not limited to.

[0045] In the first aspect, the present invention provides a marker serum hyaluronic acid (HA) for diagnosing heart failure after myocardial infarction. HA, as a biomarker, can be used to prepare a product for diagnosing heart failure after myocardial infarction. Among them, the product can be a reagent or a kit for screening, diagnosis, and detection. Specifically, the biological sample detected by the reagent or the kit is a blood sample. More specifically, the biological sample is the serum of the subject to be tested.

[0046] The present invention also provides the use of a detection kit for detecting the marker level in the preparation of a product for evaluating the prognosis of cardiac function in myocardial infarction.

[0047] Specifically, the marker level detected is the serum HA level.

[0048] When the level of HA in the tested serum contains or exceeds the threshold value, it is determined that the tested subject suffers from post-myocardial infarction heart failure.

[0049] In the second aspect, the present invention provides a marker serum HA for evaluating the prognosis of cardiac function after myocardial infarction. The evaluation is the deterioration of cardiac function within 1 month (ejection fraction decreases by more than 10%). Serum HA, as a biomarker, can be used to prepare a product for evaluating the prognosis of cardiac function in myocardial infarction, which is used to predict its short-term prognosis of cardiac function. Among them, the product can be a detection reagent or kit for evaluation. Specifically, the biological sample detected by the reagent or kit is a blood sample. More specifically, the biological sample is the serum of the subject to be tested.

[0050] The present invention also provides the use of a detection kit for detecting the level of the marker in a product for evaluating the prognosis of cardiac function in myocardial infarction. Specifically, the detection subject is a patient with myocardial infarction, and the level of the marker in the serum of the detected subject is detected, and the prognosis of the detected subject within 1 month is evaluated by the HA level in the serum, specifically, whether the cardiac function deteriorates. More specifically, when the HA level in the detected serum contains or exceeds a threshold value, it is judged that the cardiac function of the detected subject will deteriorate within 1 month.

[0051] The present invention screens out serum HA, a marker that can be used for the diagnosis of post-myocardial infarction heart failure and the prognosis evaluation of cardiac function, by analyzing the relationship between serum HA levels and the occurrence and development of post-myocardial infarction heart failure. Experimental verification shows that the serum HA levels of patients with post-myocardial infarction heart failure are significantly increased, and the serum HA levels of patients with heart failure with reduced ejection fraction (HFrEF, LVEF<40%) are further increased. The serum HA levels of patients with myocardial infarction can predict the deterioration of cardiac function within 1 month after myocardial infarction. This screens out new markers for the clinical diagnosis of post-myocardial infarction heart failure and the prognosis evaluation of cardiac function.

[0052] Example 1: Identification of molecular markers for diagnosis of heart failure after myocardial infarction

[0053] 1. Sample source

[0054] A total of 110 patients with myocardial infarction who visited the Department of Cardiology of Beijing Friendship Hospital Affiliated to Capital Medical University in Beijing from January 2024 to December 2024 were collected, including 25 patients without heart failure after myocardial infarction and 85 patients with heart failure after myocardial infarction (including 9 patients with heart failure with reduced ejection fraction (HFrEF) and 76 patients with preserved / mildly reduced ejection fraction (HFpEF / HFmrEF)).

[0055] Inclusion criteria: 1) Age ≥ 18 years old, regardless of gender; 2) Hospitalized in the Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, and diagnosed with myocardial infarction based on medical history and / or coronary angiography results during hospitalization, and routine blood, urine, and stool examinations; 3) The subjects or guardians can understand and are willing to comply with the requirements and procedures of the study protocol, voluntarily participate and sign the informed consent.

[0056] Exclusion criteria: 1) pregnant and lactating women; 2) patients with severe organ dysfunction or extreme weakness; 3) patients with poor blood pressure and blood sugar control (i.e., admission blood pressure ≥140 / 90 mmHg, or admission fasting blood sugar ≥7.0 mmol / L, or admission HbA1c ≥6.5%); 4) other situations that the researchers consider unsuitable for participation in this clinical trial.

[0057] This experimental study was a cross-sectional study that complied with the ethical standards for human experiments and was approved by the Ethics Committee of Beijing Friendship Hospital Affiliated to Capital Medical University (approval number: 2024-P2-007-01). All research subjects signed informed consent.

[0058] 2. Screening methods for heart failure markers after myocardial infarction

[0059] 2.1 General information and clinical indicators

[0060] Peripheral venous blood (10 mL) was collected from patients with myocardial infarction, and general clinical data of the patients were collected. General demographic data, blood pressure, pulse rate, other comorbidities, laboratory indicators, etc. of the subjects were collected.

[0061] 2.2 Collection and testing of blood samples

[0062] Peripheral venous blood (10 mL) was collected from patients with myocardial infarction and centrifuged at 3000 r / min for 5 min. The supernatant was placed in a new EP tube and stored at -20°C. The serum HA level of the patients was determined by enzyme linked immunosorbent assay (ELISA). The intra- and inter-batch variation rates of the kit were <15%.

[0063] 2.3 Statistical analysis

[0064] Data were processed using GraphPad Prism 9. A bar graph was used to describe the blood HA levels between groups, and a ROC curve was used to describe the diagnostic efficacy of HA levels.

[0065] 2.4 Results and Analysis

[0066] The differences in serum hyaluronic acid (HA) levels and diagnostic efficacy between the post-MI heart failure group and the post-MI non-heart failure group were compared. The analysis results are shown in Figure 1 and Figure 2The results showed that the average HA level in the post-MI heart failure group was 112.95±56.92ng / ml, and the average HA level in the post-MI non-heart failure group was 77.59±28.59ng / ml. The cutoff value for distinguishing the two groups was 90.88ng / ml, AUC=0.703, p=0.002, indicating that HA has a good diagnostic efficacy for post-MI heart failure.

[0067] Similarly, HA can distinguish between people with heart failure with reduced ejection fraction (HFrEF), people with preserved / mildly reduced ejection fraction (HFpEF / HFmrEF), and people without heart failure after myocardial infarction. The results of the analysis are shown in Figure 3 and Figure 4 The results showed that the average HA level in the post-MI group without heart failure was 77.59±28.59ng / ml, the average HA level in the HFpEF / HFmrEF group was 108.16±54.58ng / ml, and the average HA level in the HFrEF group was 153.40±63.52ng / ml. The cutoff value for distinguishing the post-MI group without heart failure from the HFpEF / HFmrEF group was 90.88ng / ml, AUC=0.684, p=0.006; the cutoff value for distinguishing the HFpEF / HFmrEF group from the HFrEF group was 131.37ng / ml, AUC=0.727, p=0.027. This indicates that HA has good diagnostic efficacy for the type of heart failure after myocardial infarction.

[0068] Example 2: Identification of molecular markers for prognosis of cardiac function in myocardial infarction

[0069] 1. Sample source

[0070] A total of 35 patients who visited the Department of Cardiology of Beijing Friendship Hospital Affiliated to Capital Medical University in Beijing from January to December 2024 for myocardial infarction and underwent cardiac ultrasound follow-up within 1 month were collected and divided into a cardiac function deterioration group (nine cases) and a cardiac function non-deterioration group (26 cases) according to whether cardiac function deteriorated within 1 month or whether heart failure (ejection fraction decreased by more than 10%) was present.

[0071] Inclusion criteria: 1) aged ≥18 years, regardless of gender; 2) hospitalized in the Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, and diagnosed with acute myocardial infarction according to medical history and / or coronary angiography results during hospitalization, and routine blood, urine, and stool examinations were prescribed; 3) patients who underwent cardiac ultrasound follow-up within 1 month; 4) the subjects or guardians were able to understand and were willing to comply with the requirements and procedures of the study protocol, voluntarily participated, and signed the informed consent form.

[0072] Exclusion criteria: 1) pregnant and lactating women; 2) patients with severe organ dysfunction or extreme weakness; 3) patients with poor blood pressure and blood sugar control (i.e., admission blood pressure>140 / 90mmHg, or admission fasting blood sugar>7.0mmol / L, or admission HbA1c>7%); 4) other situations that the researchers believe are not suitable for participation in this clinical trial.

[0073] This experimental study is a cohort study that complies with the ethical standards for human experiments and has been approved by the Ethics Committee of Beijing Friendship Hospital Affiliated to Capital Medical University (approval number: 2024-P2-007-01). All research subjects signed informed consent.

[0074] 2. Screening methods for prognostic markers of cardiac function in coronary heart disease

[0075] 2.1 General information and clinical indicators

[0076] Peripheral venous blood (10 mL) was collected from patients with myocardial infarction, and general clinical data of the patients were collected. General demographic data, blood pressure, pulse rate, other comorbidities, laboratory indicators, etc. of the subjects were collected.

[0077] 2.2 Collection and testing of blood samples

[0078] Peripheral venous blood (10 mL) was collected from patients with myocardial infarction and centrifuged at 3000 r / min for 5 min. The supernatant was placed in a new EP tube and stored at -20°C. The serum HA level of patients was determined by enzyme linked immunosorbent assay (ELISA) (abcam Biotech, USA). The intra- and inter-batch variation rates of the kit were <15%.

[0079] 2.3 Statistical analysis

[0080] Data were processed using GraphPad Prism 9. A bar graph was used to describe the blood HA levels between groups, and a ROC curve was used to describe the diagnostic efficacy of HA levels.

[0081] 2.4 Results and Analysis

[0082] The difference in serum HA levels and diagnostic efficacy between the heart function deterioration group and the heart function non-deterioration group were compared. The analysis results are shown in Figure 5 and Figure 6The results showed that the average HA level in the group with worsening heart function within one month was 116.30±26.93ng / ml, and the average HA level in the group without worsening heart function was 85.23±33.77ng / ml. The cutoff value for distinguishing the two groups was 92.21ng / ml, AUC=0.764, p=0.0411. This shows that serum hyaluronic acid (HA) level has a good predictive ability for worsening heart function within one month.

[0083] From the results of the above embodiments, it can be seen that when the serum hyaluronic acid (HA) level includes or exceeds 90.88ng / ml, the diagnosis of combined heart failure after myocardial infarction should be considered; when the HA level includes or exceeds 131.37ng / ml, the diagnosis of combined heart failure with reduced ejection fraction (HFrEF) should be considered; when the HA level includes or exceeds 90.88ng / ml, but does not exceed 131.37ng / ml, the diagnosis of combined heart failure with preserved ejection fraction / mildly reduced ejection fraction (HFpEF / HFmrEF) should be considered; when the HA level includes or exceeds 92.21ng / ml, the patient should be alert to the deterioration of cardiac function within 1 month. Serum HA levels can be used as an auxiliary biomarker for the diagnosis of heart failure after myocardial infarction and the prognosis of cardiac function. By preparing products for detecting serum HA, such as test kits, etc., determining its level can be used for auxiliary diagnosis of heart failure after myocardial infarction and prognosis of cardiac function evaluation, which is simple and easy to implement.

[0084] The above embodiments are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Use of hyaluronic acid (HA) as a marker in the preparation of diagnostic products for post-myocardial infarction heart failure in patients with myocardial infarction.

2. The use according to claim 1, characterized in that The sample is derived from the serum of a patient with myocardial infarction; preferably, the product comprises a reagent or a kit.

3. The use according to claim 1, characterized in that Diagnosis of post-myocardial infarction heart failure is achieved in the following manner: the HA level in the serum of the detected subject is detected by the product, and when the HA level in the serum of the detected subject contains or exceeds a threshold, it is determined that the detected subject suffers from post-myocardial infarction heart failure; Preferably, the threshold value is 90.88 ng / ml, and the threshold value is the first threshold value; More preferably, the threshold is 131.37 ng / ml, then the subject is judged to suffer from heart failure with reduced ejection fraction in heart failure after myocardial infarction, and the threshold is the second threshold; More preferably, when the HA level in the serum of the detected subject is detected to be between the first threshold value and the second threshold value, the detected subject is judged to suffer from heart failure with preserved ejection fraction or heart failure with mildly reduced ejection fraction in post-myocardial infarction heart failure.

4. Use of a reagent for quantitatively detecting a marker in the preparation of a diagnostic product for post-myocardial infarction heart failure in patients with myocardial infarction, wherein the marker includes HA; Preferably, the reagent is used to detect the HA level in the serum of the detected subject, and when the HA level in the serum of the detected subject contains or exceeds a threshold value, it is determined that the detected subject suffers from post-myocardial infarction heart failure; Preferably, the threshold value is 90.88 ng / ml, and the threshold value is the first threshold value; More preferably, the threshold is 131.37 ng / ml, then the subject is judged to suffer from heart failure with reduced ejection fraction in heart failure after myocardial infarction, and the threshold is the second threshold; More preferably, when the HA level in the serum of the detected subject is detected to be between the first threshold value and the second threshold value, the detected subject is judged to suffer from heart failure with preserved ejection fraction or heart failure with mildly reduced ejection fraction in post-myocardial infarction heart failure.

5. A post-myocardial infarction heart failure diagnosis system for patients with myocardial infarction, characterized in that: include A detection device for obtaining the level of a marker in the serum of a subject being detected, wherein the marker includes HA; A judging device, when the HA level in the serum of the tested subject is detected to contain or exceed a threshold value, then judging that the tested subject suffers from post-myocardial infarction heart failure; Preferably, the threshold value is 90.88 ng / ml, and the threshold value is the first threshold value; More preferably, the threshold is 131.37 ng / ml, then the subject is judged to suffer from heart failure with reduced ejection fraction in heart failure after myocardial infarction, and the threshold is the second threshold; More preferably, when the HA level in the serum of the detected subject is detected to be between the first threshold value and the second threshold value, the detected subject is judged to suffer from heart failure with preserved ejection fraction or heart failure with mildly reduced ejection fraction in post-myocardial infarction heart failure.

6. The use of HA as a marker in the preparation of products for evaluating the prognosis of cardiac function in patients with myocardial infarction.

7. The use according to claim 6, characterized in that The sample is derived from the serum of a patient with myocardial infarction; preferably, the product comprises a reagent or a kit.

8. The use according to claim 6, characterized in that The prognosis assessment of cardiac function after myocardial infarction is achieved in the following manner: the HA level in the serum of the tested subject is detected by the product, and when the HA level in the serum of the tested subject contains or exceeds a threshold, it is judged that the cardiac function of the tested subject will deteriorate within 1 month; Preferably, the threshold is 92.21 ng / m, and the threshold is the third threshold.

9. Use of a reagent for quantitatively detecting a marker in the preparation of a prognostic assessment of cardiac function after myocardial infarction, wherein the marker includes HA.

10. A post-myocardial infarction heart failure screening, diagnosis, and detection system, characterized in that: include A detection device for obtaining the level of a marker in the serum of a subject being detected, wherein the marker includes HA; The judging device judges that the cardiac function of the tested subject will deteriorate within 1 month when the HA level in the serum of the tested subject is detected to contain or exceed a threshold value; Preferably, the threshold is 92.21 ng / m, and the threshold is the third threshold.

Images